Chile’s competition prosecutor, the FNE, has requested its counterpart, the Tribunal for the Defense of Free Competition (TDLC) to penalize pharmaceutical lab GD Searle LLC with the highest possible amount allowed by the country’s antitrust laws. The prosecutors have determined that Searle, has repeatedly blocked and hampered the arrival of new competitors to their CELEBRA drug brand (sold in partnership with Pfizer Chile SA), affecting other products with the active ingredient Celecoxib.
The prosecution’s investigation, dating back to 2015, determined that Searle LLC had held a patent granting it exclusive rights to the use of the Celecoxib active ingredient until 2014. It was during this same year that Searle sought a second patent to protect CELEBRA and other Celecoxib medications with the molecule, extending this protection to the year 2029, despite not representing any palpable innovation.
Celecoxib is used in the treatment of chronic illness, affecting mostly the elderly who are often required to consume the medication daily, over long periods of time and at great monetary cost. In this sense, Prosecutor Felipe Irarrázabal declared that “the discussion regarding this problem will not stop at the legislation of industrial property, as this law should be made compatible with competition law in order for definitive benefits to be felt by consumers, especially once an initial monopoly granted by the state has expired.”
Full Content: FNE
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
European Music Streaming Firms Rally Against Apple’s Proposed Remedies
May 9, 2024 by
CPI
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI